SBTX.L Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 18:27):

SkinBioTherapeutics plc, a life science company, engages in the research and development of technology that harnesses the human microbiome to improve health...

Stats
Šios dienos apimtis	206 658
Vidutinė apimtis	715 946
Rinkos kapitalizacija	18.54M
EPS	£0 ( 2024-03-25 )
Last Dividend	£0 ( N/A )
Next Dividend	£0 ( N/A )
P/E	-4.62
ATR14	£0.225 (2.43%)

SkinBioTherapeutics PLC Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

SkinBioTherapeutics PLC Finansinės ataskaitos

Annual	2022
Pajamos:	£132 057
Bruto pelnas:	£41 653.00 (31.54 %)
EPS:	£-0.0172

FY	2022
Pajamos:	£132 057
Bruto pelnas:	£41 653.00 (31.54 %)
EPS:	£-0.0172

FY	2022
Pajamos:	£74 761.00
Bruto pelnas:	£45 337.00 (60.64 %)
EPS:	£-0.0161

FY	2021
Pajamos:	£0.00
Bruto pelnas:	£0.00 (0.00 %)
EPS:	£-0.0112

Financial Reports:

No articles found.

SkinBioTherapeutics PLC

SkinBioTherapeutics plc, a life science company, engages in the research and development of technology that harnesses the human microbiome to improve health. The company develops SkinBiotix technology that can enhance the barrier effect of skin models, protect skin from infections, and repair wounds; and AxisBiotix that focuses on the gut-skin relationship and is designed to alleviate the symptoms associated with psoriasis. It serves cosmetic skincare, food supplements, medical skin care, infection control, and pharmaceutical skincare markets. The company has a collaboration agreement with Croda Plc; the University of Manchester to develop immune-supporting microbiome formulations; and Winclove Probiotics B.V. for the development of a probiotic blend of good bacterial strains based on the modifying properties of specific bacterial species in known psoriasis pathways. The company was formerly known as Skinbiotix Ltd and changed its name to SkinBioTherapeutics plc in December 2016. SkinBioTherapeutics plc was incorporated in 2015 and is based in Newcastle upon Tyne, the United Kingdom.